Tobin Juvenal Sells 9,050 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 9,050 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $35.04, for a total transaction of $317,112.00. Following the sale, the insider owned 66,914 shares in the company, valued at $2,344,666.56. This represents a 11.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Down 2.2%

NASDAQ CSTL opened at $33.50 on Friday. Castle Biosciences, Inc. has a 52 week low of $17.72 and a 52 week high of $44.28. The company has a fifty day moving average of $27.24 and a two-hundred day moving average of $25.47. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -50.76 and a beta of 0.98. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to the consensus estimate of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. On average, analysts predict that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Castle Biosciences

Several institutional investors have recently added to or reduced their stakes in CSTL. Advisors Capital Management LLC purchased a new position in Castle Biosciences in the second quarter valued at about $5,681,000. Summit Partners Public Asset Management LLC lifted its position in shares of Castle Biosciences by 164.7% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after acquiring an additional 658,725 shares in the last quarter. SummitTX Capital L.P. boosted its stake in shares of Castle Biosciences by 285.0% during the 1st quarter. SummitTX Capital L.P. now owns 67,033 shares of the company’s stock worth $1,646,000 after purchasing an additional 49,623 shares during the last quarter. Quantinno Capital Management LP grew its stake in Castle Biosciences by 387.3% in the 1st quarter. Quantinno Capital Management LP now owns 45,476 shares of the company’s stock worth $1,116,000 after acquiring an additional 36,144 shares during the period. Finally, AIGH Capital Management LLC acquired a new position in Castle Biosciences in the second quarter valued at $13,001,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. BTIG Research increased their target price on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research report on Friday, July 31st. Finally, Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.